[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"risk-stratification\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:risk-stratification":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100640251","trajectory-based-phenotyping-after-coronary-artery-bypass-surgery-100640251",false,"NCT07598682","Trajectory-Based Phenotyping After Coronary Artery Bypass Surgery","Early Postoperative Trajectory-Based Phenotyping Improves Risk Stratification Beyond EuroSCORE in Patients Undergoing Coronary Artery Bypass Grafting","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Patients who underwent elective on-pump coronary artery bypass grafting\n* Patients operated between January 1, 2022 and December 31, 2025\n* Patients with available perioperative clinical and laboratory data required for analysis\n\nExclusion Criteria:\n\n* Patients undergoing emergency surgery\n* Patients undergoing concomitant valve surgery\n* Patients with missing or inconsistent key clinical or laboratory data","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","Coronary artery bypass grafting is a commonly performed heart surgery, but patients may have different risks for postoperative complications even when their preoperative risk scores are similar. EuroSCORE II is widely used to estimate surgical risk before cardiac surgery, but it may not fully reflect how the body responds during the early postoperative period.\n\nThis retrospective observational study will evaluate adult patients who underwent elective coronary artery bypass grafting with cardiopulmonary bypass between January 1, 2022 and December 31, 2025. The study will use existing hospital records and laboratory data. No additional treatment, test, or intervention will be given to patients as part of this study.\n\nThe main aim is to examine whether early postoperative changes in inflammatory and renal laboratory markers can identify different patient subgroups, called phenotypes. These markers include neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, triglyceride-glucose index, and serum creatinine. The study will evaluate whether these phenotype groups are associated with postoperative acute kidney injury and prolonged intensive care unit stay.\n\nThe study will also assess whether this early postoperative phenotype-based classification provides additional risk information beyond EuroSCORE II.",[24,25,26,27],"Coronary Artery Bypass Grafting","Postoperative Acute Kidney Injury","Postoperative Complications","Risk Stratification",[29,30,31,32],"Coronary artery bypass grafting","Postoperative phenotyping","EuroSCORE II","Risk stratification","NOT_YET_RECRUITING","2026-05-13",{"date":36,"type":37},"2026-05-20","ACTUAL",{"date":39,"type":20},"2026-05-07",{"date":41,"type":20},"2026-07-01",{"name":43,"class":44},"Bursa Sevket Yilmaz Training and Research Hospital","OTHER_GOV",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":60,"studyType":21,"phases":4,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100621521","personalized-mammographic-screening-in-norway-100621521","NCT07371702","PERsonalized Mammographic Screening in Norway","PERsonalized Mammographic Screening in Norway; Additional Examination for Women With Increased Risk of Breast Cancer","PERMS","Inclusion Criteria:\n\n* invited to screening\n* extremely dense breast (Study A) or a false positive screening result (Study B)\n\nExclusion Criteria:\n\n* Opted out or not signed written consent related to the study\n* Women who have opted out from giving us permission to use screening data for quality assurance and research",true,"FEMALE","50 Years","71 Years",{"count":59,"type":20},3000,"2 Years","The aim of this study is to assess attendance among women invited to additional breast imaging because they were identified as having an increased risk of breast cancer at screening. High-risk women were defined in two studies: Study A; women with high mammographic density, representing approximately 3-5% of screened women, and Study B; women with a false-positive screening result. Women in Study A will be offered an additional screening examination with digital breast tomosynthesis immediately within 6 months after the screening examination. Women in Study B will be offered an additional standard digital mammography examination one year after their initial screening.",[63,64,27],"Breast Cancer","Mammographic Breast Density",[66,67,68],"Breast Cancer Screening","personalized screening","breast cancer screening; personalized screening","2026-01-27",{"date":71,"type":37},"2026-01-29",{"date":73,"type":20},"2026-01",{"date":75,"type":20},"2033-12",{"name":77,"class":44},"Norwegian Institute of Public Health",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":54,"sex":16,"minAge":56,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":45},"100539662","effectiveness-of-risk-based-sequential-screening-for-esophageal-and-gastric-cancer-100539662","NCT06306755","Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer","Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer: A Community-Based Randomized Controlled Trial","ERSS-EGC","Inclusion Criteria:\n\n* Permanent residency in the target villages in Xun County, Henan Province, China;\n* Aged 50 to 69 at the enrollment;\n* Voluntarily participate in this study and provide informed consent.\n\nExclusion Criteria:\n\n* Had a history of endoscopic examination within 5 years prior to the initial interview;\n* Had a history of cancer;\n* Had a history of mental disorder;\n* Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV);\n* Had severe cardiovascular and cerebrovascular diseases;\n* Had severe respiratory disease, dyspnea, or asthmaticus status;\n* Had retropharyngeal abscess, severe spinal deformity, or aortic aneurysm;\n* With physical debility unable to tolerate endoscopic examination, or with difficulty in achieving sedation and self-control;\n* In the acute phase of corrosive inflammation of the upper gastrointestinal tract, or with suspected perforation of the upper gastrointestinal tract;\n* Had massive ascites, severe abdominal distension, or severe esophageal varices;\n* Pregnancy;\n* Had severe history of allergies;\n* Had propensity for bleeding (coagulopathy);\n* Others unable to tolerate the clinical examinations involved in this study.","69 Years",{"count":88,"type":20},21000,"INTERVENTIONAL",[91],"NA","To evaluate the feasibility, applicability, effectiveness, and health-economic value of the risk-based sequential screening modality for esophageal and gastric cancers, the investigators aim to initiate a community-based randomized controlled trial in Xun County, Henan Province, which is a high-risk region of upper gastrointestinal cancer (UGIC) in northern China.\n\nA total of 258 target villages from all the 11 communities (townships and streets) in Xun County will be randomly selected and assigned to the sequential screening group and the universal screening group at a ratio of 2:1 and the total sample size will be 21,000.\n\nIn the sequential screening group, participants in the top 50% risk level (i.e., stratified as the high-risk subgroup) will be offered a standard upper gastrointestinal endoscopic screening. In contrast, all participants in the universal screening group will receive the endoscopic examination. The surveillance strategy for participants with screening-detected premalignant lesions in the sequential screening group will be tailored based on individualized risk assessment using endoscopic characteristics, pathological diagnosis, and biomarkers. Surveillance for participants in the universal screening group will adhere to current guidelines for UGIC screening and clinical treatment.\n\nDetection rates of upper gastrointestinal malignant lesions, early-stage malignant lesions and premalignant lesions, and health-economic indicators such as the unit cost per detected malignant lesions will be compared between the two groups.",[94,95,96,97,27],"Esophageal Cancer","Gastric Cancer","Precision Screening","Sequential Screening","RECRUITING","2025-01-21",{"date":101,"type":37},"2025-01-24",{"date":103,"type":37},"2024-06-25",{"date":105,"type":20},"2034-12",{"name":107,"class":108},"Peking University Cancer Hospital & Institute","OTHER"]